Brief: Combangio, Inc., A Wholly Owned Subsidiary Of Kala Pharmaceuticals, Awarded $15 Million By California Institute For Regenerative Medicine To Support Ongoing Kpi-012 Program For The Treatment Of Pced

KALA BIO

28/04/2023 14:07

Kala Pharmaceuticals Inc  KALA.O :
    * COMBANGIO, INC., A WHOLLY OWNED SUBSIDIARY OF KALA
PHARMACEUTICALS, AWARDED $15 MILLION BY CALIFORNIA INSTITUTE FOR
REGENERATIVE MEDICINE TO SUPPORT ONGOING KPI-012 PROGRAM FOR THE
TREATMENT OF PCED

Source text for Eikon:  ID:nGNX6ktZsl 
Further company coverage:  KALA.O